Dexcom Inc (DXCM) 31.88 $DXCM
Global mHealth Monitoring And Diagnostic Medical Devices Market 2013-2019: Focus On Medical Devices With In-Built Plug-Ins For Connectivity
M2 - Tue May 13, 10:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7zxll5/mhealth) has announced the addition of the "mHealth Monitoring And Diagnostic Medical Devices Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019" report to their offering. The mHealth monitoring and diagnostic devices market has been segmented into seven major product types, namely, glucose monitors, blood pressure monitors, pulse oximeters, cardiac monitors, sleep apnea monitors, multi-parameter monitoring devices and others (fetal monitors, neurological monitors) devices. The market for these devices has been extensively analyzed on the basis of factors such as healthcare and monitoring applications, geographic presence and technological developments. The market size and forecasts in terms of revenue (USD million) for each of these segments have been provided for the period 2013 to 2019, considering 2012 as the base year. The mHealth monitoring and diagnostic devices market report also provides the compounded annual growth rate (CAGR) for each segment of the market for the forecast period 2013 to 2019. Geographically, the mHealth monitoring and diagnostic devices market has been segmented into four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecast for each region has been provided for the period 2011 to 2019 along with the CAGR (%) for the forecast period 2013 to 2019. The study also includes qualitative analysis of the competitive scenario in these regions. The market overview section of the mHealth monitoring and diagnostic devices market report comprises a qualitative analysis of the overall market considering the factors determining market dynamics such as drivers, restraints and opportunities, along with Porter's five force analysis and market attractiveness analysis. A PESTLE analysis has also been done while estimating individual geographies in order to provide current as well as future status. The mHealth monitoring and diagnostic devices market report also provides a highlight of the competitive landscape of the market, wherein the heat map analysis of the leading players in the market in terms of products offered by the companies has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and accentuate market shares. The report concludes with the profiles of major players in the mHealth monitoring and diagnostic devices market such as AT&T, Inc., Bayer HealthCare AG, BioTelemetry, Inc. (CardioNet, Inc.), Boston Scientific Corporation, DexCom, Inc., Dr?ger AG, F. Hoffmann La-Roche Ltd., Johnson & Johnson, LifeWatch AG, Masimo Corporation, Medtronic, Inc. and Omron Healthcare. The global mHealth monitoring and diagnostic medical devices market is segmented as follows: mHealth Monitoring and Diagnostic Medical Devices Market, by Product Type - Glucose Monitors - Blood Pressure Monitors - Cardiac Monitors - Pulse Oximeters - Sleep Apnea Monitors - Multi-parameter Monitors - Others Companies Mentioned - Bayer HealthCare AG - BioTelemetry, Inc. (CardioNet, Inc.) - Boston Scientific Corporation - DexCom, Inc. - Dr?ger AG - F. Hoffmann-La Roche Ltd. - FitBit, Inc. - Fora Care Inc. - iHealth Labs, Inc. - Johnson & Johnson - LifeWatch AG - Masimo Corporation - Medisana AG - Medtronic, Inc. - Nonin Medical, Inc. - Omron Healthcare, Inc. - Withings, Inc. For more information visit http://www.researchandmarkets.com/research/7zxll5/mhealth
Stock Updates on Health Care Sector Bellwethers -- Research on DexCom Inc., ExamWorks, Allscripts Healthcare Solutions, and HMS Holdings
PR Newswire - Tue May 13, 9:05AM CDT
On Monday, May 12, 2014, the NASDAQ Composite ended at 4,143.86, up 1.77%, the Dow Jones Industrial Average finished the session at 16,695.47, up 0.68% and the S&P 500 closed at 1,896.65, up 0.97%. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 675.29, up 1.04%, and the index has gained 4.74% in the previous one month. Investor-Edge has initiated coverage on the following equities: DexCom, Inc. (NASDAQ: DXCM), ExamWorks Group Inc. (NYSE: EXAM), Allscripts Healthcare Solutions Inc. (NASDAQ: MDRX) and HMS Holdings Corp. (NASDAQ: HMSY). Free technical research on DXCM, EXAM, MDRX and HMSY can be downloaded upon signing up at:
Earnings Look Back: DexCom Is Down 3.8% Since Reporting Quarterly Results 1 Week Ago (DXCM)
Comtex SmarTrend(R) - Mon May 12, 11:24AM CDT
A week ago on May 1st, 2014 DexCom (NASDAQ
XCM) reported earnings and analysts, on average, expected a loss of $0.08 on sales of $43.5 million. The company actually reported a loss of $0.17 per share on sales of $47.1 million, missing EPS estimates by $0.09 and beating revenue estimates by $3.6 million. Since the company's report, shares of DexCom have fallen from $32.75 to $31.52, representing a loss of 3.8% in the past 11 days.
27.5% Return Seen to Date on SmarTrend DexCom Call (DXCM)
Comtex SmarTrend(R) - Wed May 07, 4:45PM CDT
SmarTrend identified a Downtrend for DexCom (NASDAQ XCM) on March 27th, 2014 at $40.95. In approximately 1 month, DexCom has returned 27.52% as of today's recent price of $29.68.
DexCom Misses, Sees Broader Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 8:32AM CDT
DexCom's (DXCM) total revenues surged 59.1% to $47.1 million, topping the Zacks Consensus Estimate of $44.0 million.
Look for Shares of DexCom to Potentially Rebound after Yesterday's 2.76% Sell Off
Comtex SmarTrend(R) - Fri May 02, 4:50PM CDT
DexCom (NASDAQ XCM) traded in a range yesterday that spanned from a low of $28.09 to a high of $33.94. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $31.74 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Why DexCom Inc. Shares Briefly Swooned
Sean Williams, The Motley Fool - Motley Fool - Fri May 02, 1:06PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of DexCom , a developer of continuous glucose...
DexCom, Inc. Reports First Quarter 2014 Financial Results
Business Wire - Thu May 01, 3:02PM CDT
DexCom, Inc. (Nasdaq: DXCM) today reported its unaudited financial results as of and for the quarter ended March 31, 2014.
DexCom Announces Upcoming Conference Presentations
Business Wire - Wed Apr 30, 7:31AM CDT
DexCom, Inc. (NASDAQ XCM) today announced that management will present an update on DexCom at the following upcoming investor conferences:
DexCom Schedules First Quarter 2014 Earnings Release and Conference Call for May 1, 2014 at 4:30 p.m. Eastern Time
Business Wire - Thu Apr 24, 7:31AM CDT
DexCom, Inc. (NASDAQ XCM) today announced that it plans to release its first quarter 2014 financial results after market close on Thursday, May 1, 2014. Management will hold a conference call to review the company's first quarter 2014 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at www.dexcom.com by navigating to "About," then "Investor Relations," and then "Events and Webcasts," and will be archived there for future reference.
Shares of DXCM Down 12.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Apr 23, 10:04AM CDT
SmarTrend identified a Downtrend for DexCom (NASDAQ XCM) on March 27th, 2014 at $40.95. In approximately 4 weeks, DexCom has returned 12.76% as of today's recent price of $35.72.
First Week of DXCM December 20th Options Trading
DividendChannel.com - Wed Apr 23, 9:57AM CDT
Investors in DexCom Inc saw new options become available this week, for the December 20th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly...
Balanced Outlook on Accuray - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 1:50PM CDT
Accuray posted a narrower loss of $5.4 million, or 7 cents per share for the fiscal 2014-second quarter.
1 Stock Helping Revolutionize Diabetes Monitoring
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 16, 10:41AM CDT
More than 365 million people have diabetes worldwide and estimates suggest that the number of diabetics will grow to more than half a billion people around the globe by 2030. As a result, the market for new, innovative therapies that improve how...
'Mad Money' Lightning Round: Delta Is Flying to $40
at The Street - Wed Apr 16, 5:00AM CDT
Cramer says sell LinkedIn and Arena Pharmaceuticals but buy Constellation Brands.
Jim Cramer's 'Mad Money' Recap: Fear and Loathing on Wall Street
at The Street - Tue Apr 15, 7:08PM CDT
That's what professional money managers are feeling as they try and make sense of the today's market action, Cramer says.
Delcath Systems Shares Tank on Stock Split - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 1:50PM CDT
Delcath has been going through a rough patch after it failed to win approval from U.S. Food and Drug Administration (FDA) for its Melblez liver cancer therapy device.
Why DexCom (DXCM) Stock Is Higher Today
at The Street - Thu Apr 10, 8:50AM CDT
Shares of DexCom (DXCM) are up this morning after Sterne Agee upgraded the medical device company to "buy" from "neutral" with a price target of $50.
Global mHealth Monitoring And Diagnostic Medical Devices Market 2013-2019: Focus On Medical Devices With In-Built Plug-Ins For Connectivity
M2 - Tue May 13, 10:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7zxll5/mhealth) has announced the addition of the "mHealth Monitoring And Diagnostic Medical Devices Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019" report to their offering. The mHealth monitoring and diagnostic devices market has been segmented into seven major product types, namely, glucose monitors, blood pressure monitors, pulse oximeters, cardiac monitors, sleep apnea monitors, multi-parameter monitoring devices and others (fetal monitors, neurological monitors) devices. The market for these devices has been extensively analyzed on the basis of factors such as healthcare and monitoring applications, geographic presence and technological developments. The market size and forecasts in terms of revenue (USD million) for each of these segments have been provided for the period 2013 to 2019, considering 2012 as the base year. The mHealth monitoring and diagnostic devices market report also provides the compounded annual growth rate (CAGR) for each segment of the market for the forecast period 2013 to 2019. Geographically, the mHealth monitoring and diagnostic devices market has been segmented into four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecast for each region has been provided for the period 2011 to 2019 along with the CAGR (%) for the forecast period 2013 to 2019. The study also includes qualitative analysis of the competitive scenario in these regions. The market overview section of the mHealth monitoring and diagnostic devices market report comprises a qualitative analysis of the overall market considering the factors determining market dynamics such as drivers, restraints and opportunities, along with Porter's five force analysis and market attractiveness analysis. A PESTLE analysis has also been done while estimating individual geographies in order to provide current as well as future status. The mHealth monitoring and diagnostic devices market report also provides a highlight of the competitive landscape of the market, wherein the heat map analysis of the leading players in the market in terms of products offered by the companies has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and accentuate market shares. The report concludes with the profiles of major players in the mHealth monitoring and diagnostic devices market such as AT&T, Inc., Bayer HealthCare AG, BioTelemetry, Inc. (CardioNet, Inc.), Boston Scientific Corporation, DexCom, Inc., Dr?ger AG, F. Hoffmann La-Roche Ltd., Johnson & Johnson, LifeWatch AG, Masimo Corporation, Medtronic, Inc. and Omron Healthcare. The global mHealth monitoring and diagnostic medical devices market is segmented as follows: mHealth Monitoring and Diagnostic Medical Devices Market, by Product Type - Glucose Monitors - Blood Pressure Monitors - Cardiac Monitors - Pulse Oximeters - Sleep Apnea Monitors - Multi-parameter Monitors - Others Companies Mentioned - Bayer HealthCare AG - BioTelemetry, Inc. (CardioNet, Inc.) - Boston Scientific Corporation - DexCom, Inc. - Dr?ger AG - F. Hoffmann-La Roche Ltd. - FitBit, Inc. - Fora Care Inc. - iHealth Labs, Inc. - Johnson & Johnson - LifeWatch AG - Masimo Corporation - Medisana AG - Medtronic, Inc. - Nonin Medical, Inc. - Omron Healthcare, Inc. - Withings, Inc. For more information visit http://www.researchandmarkets.com/research/7zxll5/mhealth
Stock Updates on Health Care Sector Bellwethers -- Research on DexCom Inc., ExamWorks, Allscripts Healthcare Solutions, and HMS Holdings
PR Newswire - Tue May 13, 9:05AM CDT
On Monday, May 12, 2014, the NASDAQ Composite ended at 4,143.86, up 1.77%, the Dow Jones Industrial Average finished the session at 16,695.47, up 0.68% and the S&P 500 closed at 1,896.65, up 0.97%. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 675.29, up 1.04%, and the index has gained 4.74% in the previous one month. Investor-Edge has initiated coverage on the following equities: DexCom, Inc. (NASDAQ: DXCM), ExamWorks Group Inc. (NYSE: EXAM), Allscripts Healthcare Solutions Inc. (NASDAQ: MDRX) and HMS Holdings Corp. (NASDAQ: HMSY). Free technical research on DXCM, EXAM, MDRX and HMSY can be downloaded upon signing up at:
Earnings Look Back: DexCom Is Down 3.8% Since Reporting Quarterly Results 1 Week Ago (DXCM)
Comtex SmarTrend(R) - Mon May 12, 11:24AM CDT
A week ago on May 1st, 2014 DexCom (NASDAQ
XCM) reported earnings and analysts, on average, expected a loss of $0.08 on sales of $43.5 million. The company actually reported a loss of $0.17 per share on sales of $47.1 million, missing EPS estimates by $0.09 and beating revenue estimates by $3.6 million. Since the company's report, shares of DexCom have fallen from $32.75 to $31.52, representing a loss of 3.8% in the past 11 days. 27.5% Return Seen to Date on SmarTrend DexCom Call (DXCM)
Comtex SmarTrend(R) - Wed May 07, 4:45PM CDT
SmarTrend identified a Downtrend for DexCom (NASDAQ
XCM) on March 27th, 2014 at $40.95. In approximately 1 month, DexCom has returned 27.52% as of today's recent price of $29.68. DexCom Misses, Sees Broader Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 8:32AM CDT
DexCom's (DXCM) total revenues surged 59.1% to $47.1 million, topping the Zacks Consensus Estimate of $44.0 million.
Look for Shares of DexCom to Potentially Rebound after Yesterday's 2.76% Sell Off
Comtex SmarTrend(R) - Fri May 02, 4:50PM CDT
DexCom (NASDAQ
XCM) traded in a range yesterday that spanned from a low of $28.09 to a high of $33.94. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $31.74 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. Why DexCom Inc. Shares Briefly Swooned
Sean Williams, The Motley Fool - Motley Fool - Fri May 02, 1:06PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of DexCom , a developer of continuous glucose...
DexCom, Inc. Reports First Quarter 2014 Financial Results
Business Wire - Thu May 01, 3:02PM CDT
DexCom, Inc. (Nasdaq: DXCM) today reported its unaudited financial results as of and for the quarter ended March 31, 2014.
DexCom Announces Upcoming Conference Presentations
Business Wire - Wed Apr 30, 7:31AM CDT
DexCom, Inc. (NASDAQ
XCM) today announced that management will present an update on DexCom at the following upcoming investor conferences: DexCom Schedules First Quarter 2014 Earnings Release and Conference Call for May 1, 2014 at 4:30 p.m. Eastern Time
Business Wire - Thu Apr 24, 7:31AM CDT
DexCom, Inc. (NASDAQ
XCM) today announced that it plans to release its first quarter 2014 financial results after market close on Thursday, May 1, 2014. Management will hold a conference call to review the company's first quarter 2014 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at www.dexcom.com by navigating to "About," then "Investor Relations," and then "Events and Webcasts," and will be archived there for future reference. Shares of DXCM Down 12.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Apr 23, 10:04AM CDT
SmarTrend identified a Downtrend for DexCom (NASDAQ
XCM) on March 27th, 2014 at $40.95. In approximately 4 weeks, DexCom has returned 12.76% as of today's recent price of $35.72. First Week of DXCM December 20th Options Trading
DividendChannel.com - Wed Apr 23, 9:57AM CDT
Investors in DexCom Inc saw new options become available this week, for the December 20th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly...
Balanced Outlook on Accuray - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 1:50PM CDT
Accuray posted a narrower loss of $5.4 million, or 7 cents per share for the fiscal 2014-second quarter.
1 Stock Helping Revolutionize Diabetes Monitoring
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 16, 10:41AM CDT
More than 365 million people have diabetes worldwide and estimates suggest that the number of diabetics will grow to more than half a billion people around the globe by 2030. As a result, the market for new, innovative therapies that improve how...
'Mad Money' Lightning Round: Delta Is Flying to $40
at The Street - Wed Apr 16, 5:00AM CDT
Cramer says sell LinkedIn and Arena Pharmaceuticals but buy Constellation Brands.
Jim Cramer's 'Mad Money' Recap: Fear and Loathing on Wall Street
at The Street - Tue Apr 15, 7:08PM CDT
That's what professional money managers are feeling as they try and make sense of the today's market action, Cramer says.
Delcath Systems Shares Tank on Stock Split - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 1:50PM CDT
Delcath has been going through a rough patch after it failed to win approval from U.S. Food and Drug Administration (FDA) for its Melblez liver cancer therapy device.
Why DexCom (DXCM) Stock Is Higher Today
at The Street - Thu Apr 10, 8:50AM CDT
Shares of DexCom (DXCM) are up this morning after Sterne Agee upgraded the medical device company to "buy" from "neutral" with a price target of $50.
